Antibodies to alcohol-altered hepatocytes in patients with alcoholic liver disease

Late-onset fistula presenting as buttock abscess in two patients with ileo-anal J-pouches for ulcerative colitis.

Techniques in coloproctology·2004

Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancer.

Molecular pathology : MP·2002

CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size.

The British journal of radiology·2001

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

Gut·2000

Basement membrane peptides as markers of liver disease in chronic hepatitis C.

Journal of hepatology·2000

Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease.

Liver·2000

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Lancet (London, England)·2026

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Scleroderma-Like Phenotype in a Patient With Transthyretin Cardiac Amyloidosis and Acromegaly: A Triple Diagnostic Challenge.

Cureus·2026

In-vitro exposure to mercury chloride, with and without n-3 long chain polyunsaturated fatty acids, on the Th17-associated immune response in peripheral blood mononuclear cells from systemic lupus erythematosus patients.

Journal of immunotoxicology·2026

Mesenchymal Stem Cell Therapy for Multiple Sclerosis: Harnessing Immunological Properties.

Biomolecules & therapeutics·2026

Molecular underpinnings of rheumatic diseases and emerging therapeutic concepts.

Nature·2026

Adaptive immune plasticity in MASH: Functional states, pathological consequences, and regulatory mechanisms.

Hepatology communications·2026

Imaging of myositis: An overview and update.

Seminars in nuclear medicine·2026

Antibodies to alcohol-altered hepatocytes in patients with alcoholic liver disease

Related Experiment Videos

Related Concept Videos

Late-onset fistula presenting as buttock abscess in two patients with ileo-anal J-pouches for ulcerative colitis.

Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancer.

CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size.

Co-amoxiclav jaundice: clinical and histological features and HLA class II association.

Basement membrane peptides as markers of liver disease in chronic hepatitis C.

Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease.

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Scleroderma-Like Phenotype in a Patient With Transthyretin Cardiac Amyloidosis and Acromegaly: A Triple Diagnostic Challenge.

In-vitro exposure to mercury chloride, with and without n-3 long chain polyunsaturated fatty acids, on the Th17-associated immune response in peripheral blood mononuclear cells from systemic lupus erythematosus patients.

Mesenchymal Stem Cell Therapy for Multiple Sclerosis: Harnessing Immunological Properties.

Molecular underpinnings of rheumatic diseases and emerging therapeutic concepts.

Adaptive immune plasticity in MASH: Functional states, pathological consequences, and regulatory mechanisms.

Imaging of myositis: An overview and update.

Antibodies to alcohol-altered hepatocytes in patients with alcoholic liver disease

Related Experiment Videos

Related Concept Videos

Related Articles